Clinical Trial Update: Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pegylated interferon alfa-2a as maintenance therapy and its effect on liver disease progression in people co-infected with HIV and hepa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hepatitis C
• Liver Disease

Drugs mentioned

• Pegylated interferon alfa-2a (Peginterferon alfa-2a)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections, Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2011-04-27